CAMBRIDGE, UK – 15 March 2022 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on protein homeostasis by selectively inhibiting deubiquitylating enzymes (DUBs), today announced that Dr Paul Thompson, the Company’s Chief Scientific Officer, will present at the 2nd Annual Target Protein Degradation (TPD) Europe Summit in London (15-17 March).
At 9.00 AM GMT on 17 March, Dr Thompson will present on Mission’s “Novel DUB Inhibitor Platform Addressing Protein Homeostasis”. Currently Mission’s CSO, Dr Thompson joined Mission in 2016. He has over 15 years of experience in translational research and early clinical development.
The annual TPD Europe Summit provides a platform of learning, discovery, and networking opportunities, to hear about the latest developments and advancements in protein degradation from experts in the field.
– ENDS –
FOR MORE INFORMATION:
|Mission Therapeutics Ltd
Anker Lundemose MD PhD
Chief Executive Officer
Tel: +44 (0)1223 607 340
Melanie Toyne-Sewell / Katie Duffell
Tel: +44 (0) 20 7457 2013
NOTES TO EDITORS:
About Mission Therapeutics
Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of kidney disease, neurodegenerative disease, rare mitochondrial diseases and fibrosis. The Company has built a leading platform for the discovery and development of first-in-class, small molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.
Mission has strong links with key academic and research centers, including Prof. Steve Jackson’s Cancer Research UK Laboratories at the University of Cambridge Gurdon Institute, and leading UK centres in neurodegenerative diseases. The Company also has secured major industry partnerships, including its collaboration with AbbVie in November 2018, for the research and preclinical development of specified DUB inhibitors for the treatment of Alzheimer’s Disease and Parkinson’s Disease. The Company is managed by a team with broad international, commercial and clinical-science experience.
To date the Company has received £73 million / $101 million in funding and its investors comprise blue chip institutional and corporate investors including: Pfizer Venture Investments, Sofinnova Partners, Roche Venture Fund, SR One, IP Group and Rosetta Capital. Mission Therapeutics was founded in 2011 and is based at the Babraham Research Campus, Cambridge, UK.